ArticleFrontiers in oncology2025
Thyroid metastasis from hepatocellular carcinoma: a rare case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid metastasis is a relatively uncommon event in clinical practice, typically occurs in more prevalent primary tumors, including renal cell carcinoma and cancers of the gastrointestinal tract, lungs, and breast. The incidence of thyroid metastasis from primary hepatocellular carcinoma (HCC) is particularly infrequent. This case report outlines the clinical challenges and diagnostic pathway associated with a thyroid mass in a patient with HCC, highlighting the rarity and intricacy of such metastatic associations. Case Presentation: A 51-year-old male with a long-standing history of hepatitis B-related liver cirrhosis presented with a rapidly enlarging painful left-sided thyroid mass 28 months after a diagnosis of HCC. FDG-PET/CT imaging revealed a 6 cm hypodense tumor in the left lobe of the thyroid and further fine needle aspiration cytology and biopsy (FNAB) confirmed it as a metastasis from HCC. The patient underwent transcatheter arterial chemotherapy embolization (TACE) as a first attempt to control the progress of the thyroid lesion. However, subsequent imaging showed a continued progression of the lesions in liver, along with other metastatic sites. Although multiple interventions, such as radiofrequency ablation (RFA) procedures was administered due to the progression of liver cancer and embolization therapies for the thyroid, the patient experienced significant deterioration, presenting with respiratory failure due to malignant pleural effusion. Conclusions: This unique case highlights the importance of promptly considering persistent or newly developed thyroid nodules as indicative of metastatic disease. The identification of thyroid metastases, especially in the context of extensive organ involvement, often correlates with a poor prognosis. Given the distinctive physiological properties of the thyroid gland, multidisciplinary management may offer clinical benefits for such patients with complex metastatic profiles. Combining locoregional therapies with immunotherapy, particularly dual immunotherapy, may offer significant prognostic advantages. Nevertheless, these hypotheses need to be verified through large-scale clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.